KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Ionis Pharmaceuticals (IONS) over the last 17 years, with Sep 2025 value amounting to -$128.6 million.

  • Ionis Pharmaceuticals' Net Income towards Common Stockholders rose 8.45% to -$128.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$257.0 million, marking a year-over-year increase of 28.53%. This contributed to the annual value of -$454.5 million for FY2024, which is 23.84% down from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Net Income towards Common Stockholders is -$128.6 million, which was down 204.09% from $123.6 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at $223.7 million during Q4 2021, with a 5-year trough of -$147.4 million in Q3 2023.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$124.3 million (2023), whereas its average is -$88.5 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Net Income towards Common Stockholders tumbled by 949.60% in 2024 and then soared by 286.45% in 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at $223.7 million in 2021, then plummeted by 123.66% to -$52.9 million in 2022, then spiked by 81.10% to -$10.0 million in 2023, then crashed by 949.60% to -$105.0 million in 2024, then rose by 8.45% to -$128.6 million in 2025.
  • Its last three reported values are -$128.6 million in Q3 2025, $123.6 million for Q2 2025, and -$146.9 million during Q1 2025.